Back to Search Start Over

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.

Authors :
Quaranta V
Rainer C
Nielsen SR
Raymant ML
Ahmed MS
Engle DD
Taylor A
Murray T
Campbell F
Palmer DH
Tuveson DA
Mielgo A
Schmid MC
Source :
Cancer research [Cancer Res] 2018 Aug 01; Vol. 78 (15), pp. 4253-4269. Date of Electronic Publication: 2018 May 22.
Publication Year :
2018

Abstract

The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumor microenvironment that suppresses and excludes cytotoxic CD8 <superscript>+</superscript> T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not completely understood. In this study, we find that macrophage-derived granulin contributes to cytotoxic CD8 <superscript>+</superscript> T-cell exclusion in metastatic livers. Granulin expression by macrophages was induced in response to colony-stimulating factor 1. Genetic depletion of granulin reduced the formation of a fibrotic stroma, thereby allowing T-cell entry at the metastatic site. Although metastatic PDAC tumors are largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin-depleted tumors restored the antitumor immune defense and dramatically decreased metastatic tumor burden. These findings suggest that targeting granulin may serve as a potential therapeutic strategy to restore CD8 <superscript>+</superscript> T-cell infiltration in metastatic PDAC, thereby converting PDAC metastatic tumors, which are refractory to immune checkpoint inhibitors, into tumors that respond to immune checkpoint inhibition therapies. Significance: These findings uncover a mechanism by which metastatic PDAC tumors evade the immune response and provide the rationale for targeting granulin in combination with immune checkpoint inhibitors for the treatment of metastatic PDAC. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4253/F1.large.jpg Cancer Res; 78(15); 4253-69. ©2018 AACR .<br /> (©2018 American Association for Cancer Research.)

Details

Language :
English
ISSN :
1538-7445
Volume :
78
Issue :
15
Database :
MEDLINE
Journal :
Cancer research
Publication Type :
Academic Journal
Accession number :
29789416
Full Text :
https://doi.org/10.1158/0008-5472.CAN-17-3876